SLC5A2 and coronary artery disorder: At the baseline, the non-SGLT2-inhibitor group had more comorbidities, except for coronary artery disease, chronic obstructive pulmonary disease, atrial fibrillation and flutter, and rheumatoid arthritis than the SGLT2-inhibitor group.